Recent Advances in the Therapeutic Potential of Carotenoids in Preventing and Managing Metabolic Disorders

Plants, Год журнала: 2024, Номер 13(12), С. 1584 - 1584

Опубликована: Июнь 7, 2024

Carotenoids constitute compounds of significant biological interest due to their multiple activities, such as antimicrobial, anticancer, antiadipogenic, antidiabetic, and antioxidant properties. Metabolic syndrome (MetS) comprehends a series metabolic abnormalities (e.g., hypertension, obesity, atherogenic dyslipidemia) that can affect children, adolescents, the elderly. The treatment MetS involves numerous medications, which, despite efficacy, pose challenges prolonged use, high costs, various side effects. derivatives have been proposed alternative treatments because they reduce serum triglyceride concentrations, promote insulin response, inhibit adipogenesis, downregulate angiotensin-converting enzyme activity. However, carotenoids are notably sensitive pH, light exposure, temperature. This review addresses activity lycopene, lutein, fucoxanthin, astaxanthin, crocin, β-carotene towards MetS. It includes discussion sources, extraction methods, characterization techniques for analyzing carotenoids. Encapsulation approaches critically reviewed alternatives prevent degradation improve performance A brief overview physiopathology epidemiology diseases, including MetS, is also provided.

Язык: Английский

Efficacy of phentermine/topiramate extended release in weight management and metabolic profiles: A multicentre study in South Korea

Diabetes Obesity and Metabolism, Год журнала: 2025, Номер unknown

Опубликована: Март 17, 2025

Abstract Aims Clinical trials have demonstrated the effectiveness of phentermine and topiramate combination in weight management. This research evaluated efficacy safety phentermine/topiramate extended release (ER) for management, focusing on alterations body metabolic parameters routine clinical practice. Materials Methods We retrospectively included people with obesity who initiated ER between January 2020 April 2023 at 10 tertiary hospitals South Korea. The study assessed changes 5–6 months those continued, 12 months, along parameters. Total was measured using calibrated electronic scales participants light indoor clothing. Results cohort 1839 patients (540 men 1299 women), a 5–6‐month continuation rate 48%. At mean reduction 7.9%, sex‐specific losses 7.1% 8.2% women. Over 56% achieved more than 5% loss, 23% exceeding 10% reduction. Younger participants, women moderate to severe exhibited pronounced loss compared older individuals mild obesity, respectively. Concurrently, treatment improved glucose regulation, lipid profiles decreased blood pressure: HbA1c by 0.4 ± 0.9%, low‐density lipoprotein (LDL) cholesterol 32 mg/dL systolic pressure 6 15 mmHg (all p < 0.001). Treatment well‐tolerated, 15% incidence adverse events like paresthesia, dry mouth insomnia. persisted (21%) experienced an average 9.6%, 65% surpassing loss. Conclusion suggests is effective option management Korean population, though long‐term adherence remains challenge.

Язык: Английский